|
1
|
Burger M, Catto JW, Dalbagni G, Grossman
HB, Herr H, Karakiewicz P, Kassouf W, Kiemeney LA, La Vecchia C,
Shariat S and Lotan Y: Epidemiology and risk factors of urothelial
bladder cancer. Eur Urol. 63:234–241. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
McConkey DJ, Lee S, Choi W, Tran M,
Majewski T, Lee S, Siefker-Radtke A, Dinney C and Czerniak B:
Molecular genetics of bladder cancer: Emerging mechanisms of tumor
initiation and progression. Urol Oncol. 28:429–440. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kaufman DS, Shipley WU and Feldman AS:
Bladder cancer. Lancet. 374:239–249. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Serrano C, Morales R, Suárez C, Núñez I,
Valverde C, Rodón J, Humbert J, Padrós O and Carles J: Emerging
therapies for urothelial cancer. Cancer Treat Rev. 38:311–317.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Meeks JJ, Bellmunt J, Bochner BH, Clarke
NW, Daneshmand S, Galsky MD, Hahn NM, Lerner SP, Mason M, Powles T,
et al: A systematic review of neoadjuvant and adjuvant chemotherapy
for muscle-invasive bladder cancer. Eur Urol. 62:523–533. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Meyer-Siegler KL, Leifheit EC and Vera PL:
Inhibition of macrophage migration inhibitory factor decreases
proliferation and cytokine expression in bladder cancer cells. BMC
Cancer. 4:342004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Taylor JA III, Kuchel GA, Hegde P,
Voznesensky OS, Claffey K, Tsimikas J, Leng L, Bucala R and Pilbeam
C: Null mutation for macrophage migration inhibitory factor (MIF)
is associated with less aggressive bladder cancer in mice. BMC
Cancer. 7:1352007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Al-Abed Y and VanPatten S: MIF as a
disease target: ISO-1 as a proof-of-concept therapeutic. Future Med
Chem. 3:45–63. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Babu SN, Chetal G and Kumar S: Macrophage
migration inhibitory factor: A potential marker for cancer
diagnosis and therapy. Asian Pac J Cancer Prev. 13:1737–1744. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Calandra T and Roger T: Macrophage
migration inhibitory factor: A regulator of innate immunity. Nat
Rev Immunol. 3:791–800. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Larson DF and Horak K: Macrophage
migration inhibitory factor: Controller of systemic inflammation.
Crit Care. 10:1382006. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Becker-Herman S, Arie G, Medvedovsky H,
Kerem A and Shachar I: CD74 is a member of the regulated
intramembrane proteolysis-processed protein family. Mol Biol Cell.
16:5061–5069. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Borghese F and Clanchy FI: CD74: An
emerging opportunity as a therapeutic target in cancer and
autoimmune disease. Expert Opin Ther Targets. 15:237–251. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lue H, Thiele M, Franz J, Dahl E,
Speckgens S, Leng L, Fingerle-Rowson G, Bucala R, Lüscher B and
Bernhagen J: Macrophage migration inhibitory factor (MIF) promotes
cell survival by activation of the Akt pathway and role for
CSN5/JAB1 in the control of autocrine MIF activity. Oncogene.
2635:5046–5059. 2007. View Article : Google Scholar
|
|
15
|
Starlets D, Gore Y, Binsky I, Haran M,
Harpaz N, Shvidel L, Becker-Herman S, Berrebi A and Shachar I:
Cell-surface CD74 initiates a signaling cascade leading to cell
proliferation and survival. Blood. 107:4807–4816. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Choi JW, Kim Y, Lee JH and Kim YS: CD74
expression is increased in high-grade, invasive urothelial
carcinoma of the bladder. Int J Urol. 20:251–255. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Edge S, Byrd D, Compton C, Fritz A, Greene
F and Trotti A: AJCC cancer staging manual. edition 7. New York,
NY: Springer; 2010
|
|
18
|
Bradford MM: A rapid and sensitive method
for the quantitation of microgram quantities of protein utilizing
the principle of protein-dye binding. Anal Biochem. 72:248–254.
1976. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Association for assessment and
accreditation of laboratory animal care international. [Internet].
2011. AAALAC International rules of accreditation. Section 2.d.
[Cited April 2012]. http://www.aaalac.org/accreditation/rules.cfm
|
|
20
|
Offersen BV, Pfeiffer P, Hamilton-Dutoit S
and Overgaard J: Patterns of angiogenesis in nonsmall-cell lung
carcinoma. Cancer. 91:1500–1509. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cooke G, Armstrong ME and Donnelly SC:
Macrophage migration inhibitory factor (MIF), enzymatic activity
and the inflammatory response. Biofactors. 35:165–168. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Conroy H, Mawhinney L and Donnelly SC:
Inflammation and cancer: Macrophage migration inhibitory factor
(MIF)-the potential missing link. QJM. 103:831–836. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bernhagen J, Krohn R, Lue H, Gregory JL,
Zernecke A, Koenen RR, Dewor M, Georgiev I, Schober A, Leng L, et
al: MIF is a noncognate ligand of CXC chemokine receptors in
inflammatory and atherogenic cell recruitment. Nat Med. 13:587–596.
2007. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cheng RJ, Deng WG, Niu CB, Li YY and Fu Y:
Expression of macrophage migration inhibitory factor and CD74 in
cervical squamous cell carcinoma. Int J Gynecol Cancer.
21:1004–1012. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zheng YX, Yang M, Rong TT, Yuan XL, Ma YH,
Wang ZH, Shen LS and Cui L: CD74 and macrophage migration
inhibitory factor as therapeutic targets in gastric cancer. World J
Gastroenterol. 18:2253–2261. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Metodieva G, Nogueira-de-Souza NC,
Greenwood C, Al-Janabi K, Leng L, Bucala R and Metodiev MV:
CD74-dependent deregulation of the tumor suppressor scribble in
human epithelial and breast cancer cells. Neoplasia. 15:660–668.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Matsuura S, Shinmura K, Kamo T, Igarashi
H, Maruyama K, Tajima M, Ogawa H, Tanahashi M, Niwa H, Funai K, et
al: CD74-ROS1 fusion transcripts in resected non-small cell lung
carcinoma. Oncol Rep. 30:1675–1680. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bifulco C, McDaniel K, Leng L and Bucala
R: Tumor growth-promoting properties of macrophage migration
inhibitory factor. Curr Pharm Des. 14:3790–3801. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hadler-Olsen E, Winberg JO and
Uhlin-Hansen L: Matrix metalloproteinases in cancer: Their value as
diagnostic and prognostic markers and therapeutic targets. Tumour
Biol. 34:2041–2051. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Khoufache K, Bazin S, Girard K,
Guillemette J, Roy MC, Verreault JP, Al-Abed Y, Foster W and Akoum
A: Macrophage migration inhibitory factor antagonist blocks the
development of endometriosis in vivo. PLoS One. 7:e372642012.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Giannice R, Erreni M, Allavena P,
Buscaglia M and Tozzi R: Chemokines mRNA expression in relation to
the Macrophage migration inhibitory factor (MIF) mRNA and vascular
endothelial growth factor (VEGF) mRNA expression in the
microenvironment of endometrial cancer tissue and normal
endometrium: A pilot study. Cytokine. 64:509–515. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Cao WG, Morin M, Sengers V, Metz C, Roger
T, Maheux R and Akoum A: Tumour necrosis factor-alpha up-regulates
macrophage migration inhibitory factor expression in endometrial
stromal cells via the nuclear transcription factor NF-kappaB. Hum
Reprod. 21:421–428. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Stein R, Mattes MJ, Cardillo TM, Hansen
HJ, Chang CH, Burton J, Govindan S and Goldenberg DM: CD74: A new
candidate target for the immunotherapy of B-cell neoplasms. Clin
Cancer Res. 13:S5556–S5563. 2007. View Article : Google Scholar
|
|
34
|
Berkova Z, Tao RH and Samaniego F:
Milatuzumab-a promising new immunotherapeutic agent. Expert Opin
Investig Drugs. 19:141–149. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Stein R, Smith MR, Chen S, Zalath M and
Goldenberg DM: Combining milatuzumab with bortezomib, doxorubicin,
or dexamethasone improves responses in multiple myeloma cell lines.
Clin Cancer Res. 15:2808–2817. 2009. View Article : Google Scholar : PubMed/NCBI
|
